Not a huge deal imo. Let’s say the hold was lifted today - wouldn’t they still need time to get all the other stuff going? Any reason why all that other stuff (trial design, publishing HIV, partnership hunt, NASH - Noureddin presenting at 3 sessions during AASLD liver meeting 11/4-11/8, etc) isn’t going on in parallel anyway? As many have said, BLA was low hopes in investor minds the past few months - if anything, this increases the probability of a successful Amarex outcome which is a positive and can offset funding needs. Lower cash burn for now as well given BLA withdrawal.

Cyrus is doing fine imo, will see what the next few months brings and then of course the years beyond.

***He sees LL as potentially becoming “Standard of care” for NASH - did that [cash] register?! Maybe listen to that sentence a few times over and over.***

Guaranteed that’s why Cyrus is here as a start with plenty to follow up after.